Has anyone dealt with compounded tirzepatide reconstitution?

PharmacoVig_BOS said:

The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

GraceAZ_72 said:

Agreed, and it is worth saying that rounding to the nearest whole unit is usually acceptable at maintenance doses and is not acceptable at the bottom…

Thank you for spelling out the reasoning rather than just the conclusion. Sending this to two other people who asked me the same thing last week.

PharmacoVig_BOS said:

The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

Pushing back on PharmacoVig_BOS here. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

paul_denver said:

Two of us with identical vials and identical diluent arrived at different unit counts, which means one of us has a conceptual error rather than a…

dosing arithmetic — critical reminder about tirzepatide dose equivalence across formulations:

Mounjaro KwikPen and compounded tirzepatide are the same molecule but:

• KwikPen is ready to inject, no mixing needed
• Compounded requires reconstitution and proper syringe technique
• Verify your compounded concentration before each injection
• Never assume 1 vial = 1 dose without checking the math

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. No action needed from anybody.